1.Consensus Update for Systemic Treatment of Atopic Dermatitis
Ji Hyun LEE ; Jung Eun KIM ; Gyeong-Hun PARK ; Jung Min BAE ; Ji Yeon BYUN ; Min Kyung SHIN ; Tae Young HAN ; Seung Phil HONG ; Yong Hyun JANG ; Hye One KIM ; Chan Ho NA ; Bark-Lynn LEW ; JiYoung AHN ; Chang Ook PARK ; Young-Joon SEO ; Yang Won LEE ; Sang Wook SON ; Eung Ho CHOI ; Young Lip PARK ; Joo Young ROH
Annals of Dermatology 2021;33(6):497-514
Background:
In 2015, the Korean Atopic Dermatitis Association (KADA) working group published consensus guidelines for treating atopic dermatitis (AD).
Objective:
We aimed to provide updated consensus recommendations for systemic treatment of AD in South Korea based on recent evidence and experience.
Methods:
We compiled a database of references from relevant systematic reviews and guidelines on the systemic management of AD. Evidence for each statement was graded and classified based on thestrength of the recommendation. Forty-two council members from the KADA participated in three rounds of voting to establish a consensus on expert recommendations.
Results:
We do not recommend long-term treatment with systemic steroids forpatients with moderate-to-severe AD due to the risk of adverse effects. We recommend treatment with cyclosporine or dupilumab and selective treatment with methotrexate or azathioprine for patients with moderate-to-severe AD. We suggest treatment with antihistamines as an option for alleviating clinical symptoms of AD. We recommend selective treatment with narrowband ultraviolet B for patients with chronic moderate-to-severe AD. We do not recommend treatment with oral antibiotics for patients with moderate-to-severe AD but who have no signs of infection. We did not reach a consensus on recommendations for treatment with allergen-specific immunotherapy, probiotics, evening primrose oil, orvitamin D for patients with moderate-to-severe AD. We also recommend educational interventions and counselling for patients with AD and caregivers to improve the treatment success rate.
Conclusion
We look forward to implementing a new and updated consensus of systemic therapy in controlling patients with moderate-to-severe AD.
2.Driving-Related Adverse Events in the Elderly Men: A Population-Based Prospective Cohort Study
Jae Sung KIM ; Jong Bin BAE ; Kyuhee HAN ; Jong Woo HONG ; Ji Hyun HAN ; Tae Hui KIM ; Kyung Phil KWAK ; Kayoung KIM ; Bong Jo KIM ; Shin Gyeom KIM ; Jeong Lan KIM ; Tae Hyun KIM ; Seok Woo MOON ; Jae Young PARK ; Joon Hyuk PARK ; Seonjeong BYUN ; Seung Wan SUH ; Ji Young SEO ; Yoonseop SO ; Seung-Ho RYU ; Jong Chul YOUN ; Kyoung Hwan LEE ; Dong Young LEE ; Dong-Woo LEE ; Seok Bum LEE ; Jung Jae LEE ; Ju Ri LEE ; Hyeon JEONG ; Hyun-Ghang JEONG ; Jin Hyeong JHOO ; Ji Won HAN ; Ki Woong KIM
Psychiatry Investigation 2020;17(8):744-750
Objective:
This study estimated the incidence of driving-related adverse events and examined the association of cognitive function with the risk of future driving-related adverse events in the elderly Korean male population.
Methods:
We analyzed 1,172 male drivers aged 60 years or older in the Korean Longitudinal Study on Cognitive Aging and Dementia (KLOSCAD). Using the data from Korean National Police Agency, we classified the participants into three groups: safe driving (drove for 2 years after baseline without a traffic accident or repeated violations), driving cessation (stopped driving), and risky driving (one or more traffic accidents or repeated violations). We estimated the incidences of driving cessation and risky driving, and examined the effect of cognitive function on their risks.
Results:
The incidence of driving cessation and risky driving in the Korean male drivers aged 60 years or older was 19.3 and 69.9 per 1,000 person-years respectively and increased in the late 80s. Drivers with better baseline Word List Memory Test scores showed less risky driving (OR=0.94, p=0.039).
Conclusion
Driving-related adverse events increased in late 80s, and better memory function was protective against these events.
3.Low Diastolic Blood Pressure and Cognitive Decline in Korean Elderly People: The Korean Longitudinal Study on Cognitive Aging and Dementia
Dongyun LEE ; Bong-Jo KIM ; Ji Won HAN ; Tae Hui KIM ; Kyung Phil KWAK ; Kayoung KIM ; Shin Gyeom KIM ; Jeong Lan KIM ; Tae Hyun KIM ; Seok Woo MOON ; Jae Young PARK ; Joon Hyuk PARK ; Seonjeong BYUN ; Seung Wan SUH ; Ji Young SEO ; Yoonseop SO ; Seung-Ho RYU ; Jong Chul YOUN ; Kyoung Hwan LEE ; Dong Young LEE ; Dong Woo LEE ; Seok Bum LEE ; Jung Jae LEE ; Ju Ri LEE ; Hyeon JEONG ; Hyun-Ghang JEONG ; Jin Hyeong JHOO ; Kyuhee HAN ; Jong Woo HONG ; Jong Bin BAE ; Ki Woong KIM
Psychiatry Investigation 2020;17(1):21-28
Objective:
Cardiovascular diseases are representative risk factors for the onset of cognitive decline. The purpose of this study was to confirm the relationship between diastolic blood pressure and cognitive function in elderly people in Korea.
Methods:
Data from subjects who were enrolled in the prospective Korean Longitudinal Study on Cognitive Aging and Dementia were used in this study. Data from 701 subjects whose diastolic blood pressure range did not change (≤79 mm Hg or ≥80 mm Hg) over 2 years were analyzed. To analyze the differences in cognitive function between the groups at the 2-year follow-up, an analysis of covariance was performed with covariates, which were significantly different between the two groups, and the baseline cognitive function.
Results:
Significant differences were observed between the two groups, and the mean scores on the constructional praxis (η2=0.010) and word list recall tests (η2=0.018) in the diastolic blood pressure ≥80 mm Hg group were higher than those in the diastolic blood pressure ≤79 mm Hg group at the 2-year follow-up.
Conclusion
These results indicate that maintaining a DBP below 79 mm Hg presents a greater risk of cognitive decline in Korean elderly people.
4.Normal-But-Low Serum Folate Levels and the Risks for Cognitive Impairment
Soomin JANG ; Ji Won HAN ; Jiyoon SHIN ; Tae Hui KIM ; Kyung Phil KWAK ; Kayoung KIM ; Bong Jo KIM ; Shin Gyeom KIM ; Jeong Lan KIM ; Tae Hyun KIM ; Seok Woo MOON ; Jae Young PARK ; Joon Hyuk PARK ; Seonjeong BYUN ; Seung Wan SUH ; Jiyeong SEO ; Yoonseop SO ; Seung Ho RYU ; Jong Chul YOUN ; Kyoung Hwan LEE ; Dong Young LEE ; Dong Woo LEE ; Seok Bum LEE ; Jung Jae LEE ; Ju Ri LEE ; Hyeon JEONG ; Hyun Ghang JEONG ; Jin Hyeong JHOO ; Kyuhee HAN ; Jong Woo HONG ; Ki Woong KIM
Psychiatry Investigation 2019;16(7):532-538
OBJECTIVE: This study aimed to examine the association between normal-but-low folate levels and cognitive function in the elderly population using a prospective cohort study. METHODS: We analyzed 3,910 participants whose serum folate levels were within the normal reference range (1.5–16.9 ng/mL) at baseline evaluation in the population-based prospective cohort study named the “Korean Longitudinal Study on Cognitive Aging and Dementia.” The association between baseline folate quartile categories and baseline cognitive disorders [mild cognitive impairment (MCI) or dementia] was examined using binary logistic regression analysis adjusting for confounding variables. The risks of incident MCI and dementia associated with the decline of serum folate level during a 4-year follow-up period were examined using multinomial logistic regression analysis. RESULTS: The lowest quartile group of serum folate (≥1.5, ≤5.9 ng/mL) showed a higher risk of cognitive disorders than did the highest quartile group at baseline evaluation (odds ratio 1.314, p=0.012). Over the 4 years of follow-up, the risk of incident dementia was 2.364 times higher among subjects whose serum folate levels declined from the 2nd–4th quartile group to the 1st quartile than among those for whom it did not (p=0.031). CONCLUSION: Normal-but-low serum folate levels were associated with the risk of cognitive disorders in the elderly population, and a decline to normal-but-low serum folate levels was associated with incident dementia. Maintaining serum folate concentration above 5.9 ng/mL may be beneficial for cognitive status.
Aged
;
Cognition
;
Cognition Disorders
;
Cognitive Aging
;
Cohort Studies
;
Confounding Factors (Epidemiology)
;
Dementia
;
Folic Acid
;
Follow-Up Studies
;
Humans
;
Logistic Models
;
Longitudinal Studies
;
Prospective Studies
;
Reference Values
5.Overview of the Korean Longitudinal Study on Cognitive Aging and Dementia.
Ji Won HAN ; Tae Hui KIM ; Kyung Phil KWAK ; Kayoung KIM ; Bong Jo KIM ; Shin Gyeom KIM ; Jeong Lan KIM ; Tae Hyun KIM ; Seok Woo MOON ; Jae Young PARK ; Joon Hyuk PARK ; Seonjeong BYUN ; Seung Wan SUH ; Ji Young SEO ; Yoonseop SO ; Seung Ho RYU ; Jong Chul YOUN ; Kyoung Hwan LEE ; Dong Young LEE ; Dong Woo LEE ; Seok Bum LEE ; Jung Jae LEE ; Ju Ri LEE ; Hyeon JEONG ; Hyun Ghang JEONG ; Jin Hyeong JHOO ; Kyuhee HAN ; Jong Woo HONG ; Ki Woong KIM
Psychiatry Investigation 2018;15(8):767-774
OBJECTIVE: Due to an unprecedented rate of population aging, South Korea is facing a dementia epidemic. For this reason, the Korean Longitudinal Study on Cognitive Aging and Dementia (KLOSCAD) was launched in 2009 with support from the Korean Health Industry Development Institute to investigate the epidemiology, biopsychosocial risk factors, and outcomes of dementia and dementia-related conditions. METHODS: The KLOSCAD is the first nationwide multi-center population-based prospective cohort study. In October 2010, 12,694 individuals were randomly sampled from residents aged 60 years or older who lived in 13 districts across South Korea. In the baseline assessment, which was conducted from November 2010 through October 2012, 6,818 (53.7%) individuals participated. Follow-up assessments have been conducted every two years, with the first follow-up assessment conducted between November 2012 and October 2014, and the second between November 2014 and October 2016. The third is now in progress, and will span from November 2016 to October 2018. Diagnosis of cognitive disorders, neuropsychological battery, behavioral and psychological symptoms of dementia, activities of daily living, physical and neurologic examination and laboratory tests, life styles, quality of life, and identification of death were evaluated in each assessment. RESULTS: The cumulative drop-out rate at the second follow-up assessment was 38.7%. Dementia and mild cognitive impairment were 5.0% and 27.0%, respectively. CONCLUSION: The KLOSCAD may provide strong scientific evidence for advancing the fight against dementia both in Korea and globally.
Activities of Daily Living
;
Aging
;
Cognitive Aging*
;
Cohort Studies
;
Dementia*
;
Diagnosis
;
Epidemiology
;
Follow-Up Studies
;
Korea
;
Life Style
;
Longitudinal Studies*
;
Mild Cognitive Impairment
;
Neurologic Examination
;
Prospective Studies
;
Quality of Life
;
Risk Factors
6.A Randomized Controlled Trial of Compression Rates during Cardiopulmonary Resuscitation.
Sung Oh HWANG ; Kyoung Chul CHA ; Kyuseok KIM ; You Hwan JO ; Sung Phil CHUNG ; Je Sung YOU ; Jonghwan SHIN ; Hui Jai LEE ; Yoo Seok PARK ; Seunghwan KIM ; Sang Cheon CHOI ; Eun Jung PARK ; Won Young KIM ; Dong Woo SEO ; Sungwoo MOON ; Gapsu HAN ; Han Sung CHOI ; Hyunggoo KANG ; Seung Min PARK ; Woon Yong KWON ; Eunhee CHOI
Journal of Korean Medical Science 2016;31(9):1491-1498
The objective of this study was to compare the efficacy of cardiopulmonary resuscitation (CPR) with 120 compressions per minute (CPM) to CPR with 100 CPM in patients with non-traumatic out-of-hospital cardiac arrest. We randomly assigned patients with non-traumatic out-of-hospital cardiac arrest into two groups upon arrival to the emergency department (ED). The patients received manual CPR either with 100 CPM (CPR-100 group) or 120 CPM (CPR-120 group). The primary outcome measure was sustained restoration of spontaneous circulation (ROSC). The secondary outcome measures were survival discharge from the hospital, one-month survival, and one-month survival with good functional status. Of 470 patients with cardiac arrest, 136 patients in the CPR-100 group and 156 patients in the CPR-120 group were included in the final analysis. A total of 69 patients (50.7%) in the CPR-100 group and 67 patients (42.9%) in the CPR-120 group had ROSC (absolute difference, 7.8% points; 95% confidence interval [CI], -3.7 to 19.2%; P = 0.183). The rates of survival discharge from the hospital, one-month survival, and one-month survival with good functional status were not different between the two groups (16.9% vs. 12.8%, P = 0.325; 12.5% vs. 6.4%, P = 0.073; 5.9% vs. 2.6%, P = 0.154, respectively). We did not find differences in the resuscitation outcomes between those who received CPR with 100 CPM and those with 120 CPM. However, a large trial is warranted, with adequate power to confirm a statistically non-significant trend toward superiority of CPR with 100 CPM. (Clinical Trial Registration Information: www.cris.nih.go.kr, cris.nih.go.kr number, KCT0000231)
Cardiopulmonary Resuscitation*
;
Emergency Service, Hospital
;
Heart Arrest
;
Humans
;
Out-of-Hospital Cardiac Arrest
;
Outcome Assessment (Health Care)
;
Resuscitation
7.Urinary Nucleic Acid TSPAN13-to-S100A9 Ratio as a Diagnostic Marker in Prostate Cancer.
Chunri YAN ; Ye Hwan KIM ; Ho Won KANG ; Sung Phil SEO ; Pildu JEONG ; Il Seok LEE ; Dongho KIM ; Jung Min KIM ; Yung Hyun CHOI ; Sung Kwon MOON ; Seok Joong YUN ; Wun Jae KIM
Journal of Korean Medical Science 2015;30(12):1784-1792
The potential use of urinary nucleic acids as diagnostic markers in prostate cancer (PCa) was evaluated. Ninety-five urine samples and 234 prostate tissue samples from patients with PCa and benign prostatic hyperplasia (BPH) were analyzed. Micro-array analysis was used to identify candidate genes, which were verified by the two-gene expression ratio and validated in tissue mRNA and urinary nucleic acid cohorts. Real-time quantitative polymerase chain reaction (qPCR) was used to measure urinary nucleic acid levels and tissue mRNA expression. The TSPAN13-to-S100A9 ratio was selected to determine the diagnostic value of urinary nucleic acids in PCa (P = 0.037) and shown to be significantly higher in PCa than in BPH in the mRNA and nucleic acid cohort analyses (P < 0.001 and P = 0.013, respectively). Receiver operating characteristic (ROC) analysis showed that the area under the ROC curve was 0.898 and 0.676 in tissue mRNA cohort and urinary nucleic acid cohort, respectively. The TSPAN13-to-S100A9 ratio showed a strong potential as a diagnostic marker for PCa. The present results suggest that the analysis of urine supernatant can be used as a simple diagnostic method for PCa that can be adapted to the clinical setting in the future.
Aged
;
Aged, 80 and over
;
Biomarkers, Tumor/*genetics/*urine
;
Calgranulin B/*genetics
;
Cohort Studies
;
Humans
;
Male
;
Middle Aged
;
Nucleic Acids/*genetics/*urine
;
Oligonucleotide Array Sequence Analysis
;
Prostate/metabolism
;
Prostatic Hyperplasia/diagnosis/genetics/urine
;
Prostatic Neoplasms/diagnosis/*genetics/*urine
;
RNA, Messenger/genetics/metabolism
;
RNA, Neoplasm/genetics/metabolism
;
ROC Curve
;
Real-Time Polymerase Chain Reaction
;
Tetraspanins/*genetics
8.Consensus Guidelines for the Treatment of Atopic Dermatitis in Korea (Part II): Systemic Treatment.
Jung Eun KIM ; Hyun Jeong KIM ; Bark Lynn LEW ; Kyung Ho LEE ; Seung Phil HONG ; Yong Hyun JANG ; Kui Young PARK ; Seong Jun SEO ; Jung Min BAE ; Eung Ho CHOI ; Ki Beom SUHR ; Seung Chul LEE ; Hyun Chang KO ; Young Lip PARK ; Sang Wook SON ; Young Jun SEO ; Yang Won LEE ; Sang Hyun CHO ; Chun Wook PARK ; Joo Young ROH
Annals of Dermatology 2015;27(5):578-592
BACKGROUND: Since the treatment guidelines for atopic dermatitis (AD) were issued by the Korean Atopic Dermatitis Association (KADA) work group in 2006, there have been further advances in the systemic treatment of AD. OBJECTIVE: We aimed to establish updated evidence- and experience-based systemic treatment guidelines for Korean AD. METHODS: We compiled a database of references from relevant systematic reviews and guidelines regarding the systemic management of AD, including antihistamines, antimicrobials, systemic immunomodulators, allergen-specific immunotherapy, phototherapy, adjunctive treatment, and complementary and alternative medicines. Evidence for each statement was graded and classified based on the strength of the recommendation. Thirty-nine council members of KADA participated in the three rounds of votes and expert consensus recommendations were established. RESULTS: The use of antihistamines is recommended to relieve pruritus and to prevent exacerbation due to scratching in AD patients. Infection should be controlled as needed and long-term medication should be avoided. For moderate to severe AD patients, concomitant active treatments with systemic immunomodulators are indicated. Cyclosporine is the first choice among systemic immunomodulators and others should be considered as second-line alternatives. Allergen-specific immunotherapy could be effective in AD patients with aeroallergen hypersensitivity. Phototherapy can be useful for moderate to severe AD patients and narrow-band ultraviolet B is the most effective option. Complementary and alternative medicines cannot be recommended for treating AD. CONCLUSION: We expect these recommendations to be a reference guide for physicians and AD patients in choosing the appropriate treatment to improve quality of life and decrease unnecessary social medical costs.
Consensus*
;
Cyclosporine
;
Dermatitis
;
Dermatitis, Atopic*
;
Histamine Antagonists
;
Humans
;
Hypersensitivity
;
Immunologic Factors
;
Immunotherapy
;
Korea*
;
Phototherapy
;
Pruritus
;
Quality of Life
9.Consensus Guidelines for the Treatment of Atopic Dermatitis in Korea (Part I): General Management and Topical Treatment.
Jung Eun KIM ; Hyun Jeong KIM ; Bark Lynn LEW ; Kyung Ho LEE ; Seung Phil HONG ; Yong Hyun JANG ; Kui Young PARK ; Seong Jun SEO ; Jung Min BAE ; Eung Ho CHOI ; Ki Beom SUHR ; Seung Chul LEE ; Hyun Chang KO ; Young Lip PARK ; Sang Wook SON ; Young Jun SEO ; Yang Won LEE ; Sang Hyun CHO ; Chun Wook PARK ; Joo Young ROH
Annals of Dermatology 2015;27(5):563-577
BACKGROUND: Since the treatment guidelines for atopic dermatitis (AD) were released by the Korean Atopic Dermatitis Association (KADA) work group in 2006, there have been several advances in AD management. OBJECTIVE: We aimed to establish updated evidence- and experience-based treatment guidelines for Korean AD. METHODS: We collected a database of references from relevant systematic AD reviews and guidelines regarding general AD management such as bathing and skin care, avoidance of exacerbating factors, education and psychosocial support, and the use of moisturizers and topical anti-inflammatory and antipruritic drugs. Evidence for each statement was graded and the strength of the recommendation for each statement classified. Thirty-nine KADA council members participated in three rounds of voting to establish an expert consensus of recommendations. RESULTS: Basic AD treatment includes proper bathing and skin care, avoidance of exacerbating factors, proper education and psychosocial support, and use of moisturizers. The regular use of moisturizer has a steroid-sparing effect and reduces relapse episodes. The short- and long-term use of topical corticosteroids and calcineurin inhibitors improves AD symptoms and should be encouraged to use in an active and proactive treatment. Wet-wrap therapy can be used for rapid recovery of acute exacerbation. Topical antipruritic drugs cannot be recommended for the treatment of AD. CONCLUSION: This report provides up-to-date evidence- and experience-based treatment guidelines for AD regarding general management and topical treatment. In addition, the average agreement scores obtained by a panel of experts based on the Korean healthcare system and patient adherence are presented.
Adrenal Cortex Hormones
;
Antipruritics
;
Baths
;
Calcineurin
;
Consensus*
;
Delivery of Health Care
;
Dermatitis, Atopic*
;
Education
;
Korea*
;
Patient Compliance
;
Politics
;
Recurrence
;
Skin Care
10.Consensus Guidelines for the Treatment of Atopic Dermatitis in Korea (Part II): Systemic Treatment.
Jung Eun KIM ; Hyun Jeong KIM ; Bark Lynn LEW ; Kyung Ho LEE ; Seung Phil HONG ; Yong Hyun JANG ; Kui Young PARK ; Seong Jun SEO ; Jung Min BAE ; Eung Ho CHOI ; Ki Beom SUHR ; Seung Chul LEE ; Hyun Chang KO ; Young Lip PARK ; Sang Wook SON ; Young Jun SEO ; Yang Won LEE ; Sang Hyun CHO ; Chun Wook PARK ; Joo Young ROH
Annals of Dermatology 2015;27(5):578-592
BACKGROUND: Since the treatment guidelines for atopic dermatitis (AD) were issued by the Korean Atopic Dermatitis Association (KADA) work group in 2006, there have been further advances in the systemic treatment of AD. OBJECTIVE: We aimed to establish updated evidence- and experience-based systemic treatment guidelines for Korean AD. METHODS: We compiled a database of references from relevant systematic reviews and guidelines regarding the systemic management of AD, including antihistamines, antimicrobials, systemic immunomodulators, allergen-specific immunotherapy, phototherapy, adjunctive treatment, and complementary and alternative medicines. Evidence for each statement was graded and classified based on the strength of the recommendation. Thirty-nine council members of KADA participated in the three rounds of votes and expert consensus recommendations were established. RESULTS: The use of antihistamines is recommended to relieve pruritus and to prevent exacerbation due to scratching in AD patients. Infection should be controlled as needed and long-term medication should be avoided. For moderate to severe AD patients, concomitant active treatments with systemic immunomodulators are indicated. Cyclosporine is the first choice among systemic immunomodulators and others should be considered as second-line alternatives. Allergen-specific immunotherapy could be effective in AD patients with aeroallergen hypersensitivity. Phototherapy can be useful for moderate to severe AD patients and narrow-band ultraviolet B is the most effective option. Complementary and alternative medicines cannot be recommended for treating AD. CONCLUSION: We expect these recommendations to be a reference guide for physicians and AD patients in choosing the appropriate treatment to improve quality of life and decrease unnecessary social medical costs.
Consensus*
;
Cyclosporine
;
Dermatitis
;
Dermatitis, Atopic*
;
Histamine Antagonists
;
Humans
;
Hypersensitivity
;
Immunologic Factors
;
Immunotherapy
;
Korea*
;
Phototherapy
;
Pruritus
;
Quality of Life

Result Analysis
Print
Save
E-mail